Psoriasis is a chronic inflammatory skin disease affecting about 1-3% of the general population. 
THE RATIONALE FOR TARGETING IL-17 IN PSORIASIS
Plaque psoriasis is a chronic inflammatory skin disease affecting 1-3% of the general population causing a significant impairment of quality of life, particularly if diffuse and recalcitrant to treatments [1] . Psoriasis is commonly associated with multiple comorbidities including psoriatic arthritis (PsA), inflammatory bowel diseases (Crohn's disease and ulcerative colitis), cardio-metabolic disorders (such as myocardial infarction hypertension, obesity, diabetes, dyslipidemia, fatty liver disease, and hyperuricemia) [2] [3] [4] [5] .
The association between psoriasis and cardiometabolic comorbidities could be explained considering unhealthy life habits (i.e., smoking, over-eating, and sedentary life), the systemic nature of psoriasis-related inflammation, as well as common genetic and pathogenic pathways [5, 6] . The current understanding of the psoriasis pathogenesis assigns central importance to an interaction between acquired and innate immunity [7] . At the onset of the disease, plasmocytoid dendritic cells are activated in the dermis and produce tumor necrosis factor (TNF)-a and interleukin (IL)-23, which promote the development of T helper (Th)1 and Th17 lymphocytes which largely infiltrate psoriatic skin [8] . Th17 cells are a recently identified cluster of differentiation (CD4)? helper T cell subset which produce mainly IL-17A, IL-17F, IL-6, and, to a lesser extent, TNF-a and IL-22, which in turn are responsible for inflammatory changes and epidermal hyperplasia [9] . Notably, TNF-a also synergizes with IL-17A to induce many psoriasis-related genes in human epidermal keratinocytes [10] . IL-17A is produced not only by Th17 cells, but also by neutrophils, mast cells, and T cytotoxic cells. The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors. 
SECUKINUMAB IN CHRONIC PLAQUE PSORIASIS
Secukinumab demonstrated a favorable safety and tolerability profile with robust clinical activity, including improvements in psoriasis area and severity index (PASI) scores and investigator global assessment scores in patients with moderate-to-severe plaque psoriasis. A single infusion of secukinumab (3 mg/kg) resulted in rapid and sustained improvement of psoriasis in a double-blind, placebo-controlled, parallel-group, phase IIA proof-of-concept study on 36 patients [15] . At week 4, secukinumab was associated with an early significant reduction from baseline in mean PASI score compared to placebo (58% vs. 4%; P = 0.0001) [15] . Accordingly, 83% of secukinumab patients versus 11% of placebo patients achieved significant decreases from baseline in investigator global assessment score (P = 0.0004) [15] . Benefits were maintained at week 12, with similar rates of adverse events (AEs), including infections, in both groups [15] . Consistent with the significant decrease in skin inflammation that was clinically evident, molecular profiling of psoriatic skin samples following treatment with secukinumab showed selective modulation of cytokines, including IL-12B, IL-17A, IL-17F, IL-21, IL-22, IL-26, interferon (IFN)-c, and TNF-a [15] . These molecules are expressed by leukocyte and by tissue lineages, pointing to a diverse impact of IL-17A on multiple cellular lineages involved in psoriasis pathophysiology [15] .
Secukinumab was further evaluated in phase IIB subcutaneous (SC) dose-ranging and intravenous (IV) regimen-finding studies. In particular, a randomized, double-blind, parallel-group, placebo-controlled, doseranging study evaluated four SC doses of secukinumab [16] . Patients (n = 125) were associated with significantly greater rates of PASI 75 response at week 12 compared with placebo (82% and 57% vs. 9%; P\0.001 and P = 0.002, respectively; Table 1 ). Results also indicated that doses of secukinumab higher than 75 mg led to higher efficacy and higher doses of secukinumab may be required for some patients with greater body weight. Rates of AEs and serious AEs (SAEs) were comparable between secukinumab and placebo cohorts.
On the basis of the findings indicating the safety and efficacy of secukinumab 150 mg, a placebo-controlled phase IIB trial was conducted to assess 3 regimens of SC secukinumab 150 mg in patients (n = 404) with moderate-to-severe plaque psoriasis, including single regimen (week 0; n = 67), early (weeks 0, 1, 2, 4; n = 133), and monthly (weeks 0, 4, 8; n = 138) [17] . Early and monthly regimens resulted in significantly greater rates of PASI 75 response at week 12, the primary efficacy endpoint of the study, compared to placebo (54.5% and 42% vs. 2%; P\0.001 for both comparisons; Table 1 ) [17] . The trial also investigated maintenance treatment strategies and secukinumab showed to offer patients and physicians the choice of either a fixed interval treatment regimen (every 4 weeks) or flexible dosing [17] . However, the maintenance period revealed a favorable efficacy profile of fixed interval period (84.6% of patients) versus the on-demand regimen (67.2%) in achieving PASI 75 at least once from week 20 to week 28. In this study, an initial induction period (loading dosage) followed by the continuous treatment determined the optimal therapeutic regimen using SC 150 mg secukinumab (Fig. 1) .
Secukinumab was associated with a safety profile comparable to placebo [17] .
A similar phase IIB regimen-finding study was conducted to evaluate IV secukinumab induction regimens [18] . All secukinumab IV induction regimens were associated with significantly greater rates of PASI 75 and 90 responses at week 12 compared with placebo.
Although there were six SAEs in the secukinumab treatment cohort, none were considered by the investigators to be drugrelated. Currently, secukinumab is being tested in several phase III clinical trials including a study evaluating efficacy of withdrawal-andretreatment, a study comparing secukinumab with etanercept, a study concerning moderateto-severe palmoplantar psoriasis and another trial on PsA [19] .
SECUKINUMAB IN PSORIATIC ARTHRITIS
The efficacy and safety of secukinumab in patients with moderate-to-severe PsA was PASI psoriasis area and severity index 
SAFETY OF SECUKINUMAB IN CHRONIC PLAQUE PSORIASIS AND PSA
The crucial role of IL-17 in the innate immune response, poses IL-17 as the main driver of the host defense against extracellular bacterial (Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae), parasitic (Toxoplasma gondii) and fungal (Candida spp.) infections [21] [22] [23] . Importantly, both IL-17A and IL-17F are needed for muco-cutaneous immunity against Candida albicans, but their effects are largely redundant. Genetic deficiency in IL-17RA, in humans, is associated with recurrent or persistent muco-cutaneous infections caused by C. albicans and, to a lesser extent, S. aureus [24] .
In the aforementioned studies, secukinumab was well tolerated, with an overall good safety profile; none of the patients developed antisecukinumab antibodies and there were no reports of injection-site reactions. Most of the AEs were mild or moderate in severity, particularly infections (Table 2 ) [16] [17] [18] . Vaccination against influenza is currently recommended to patients suffering from psoriasis [25] ; previous studies have shown that vaccination against influenza virus and pneumococcus is safe with concomitant treatment with biologics like adalimumab and etanercept, and that it induces a satisfactory humoral response, whereas other agents, like rituximab, impaired vaccine effectiveness [26, 27] . Chioato et al. [28] 
CONCLUSION
Psoriasis is facing very rapid advances in the understanding of its pathogenesis that drives a fast expanding availability of new therapeutic agents. Although anti-TNF-a drugs have 
